Kim Papp

1. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
   2022/09/09 by Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg +13 · 27 citations
   Medicine · #Dermatology and Skin Diseases #Asthma and respiratory diseases #Allergic Rhinitis and Sensitization
2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
   2017/01/04 by Andrew Blauvelt, Kim Papp, Kim A. Papp +9 · 4 citations
   Immunology and Microbiology · Medicine · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Dermatology and Skin Diseases
3. Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
   2020/04/17 by Kathleen Weisel, Scott B. Berger, Scott Berger +10 · 25 citations
   Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · Medicine · #Psoriasis: Treatment and Pathogenesis #NF-κB Signaling Pathways #Cytokine Signaling Pathways and Interactions
4. Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )
   2020/04/21 by Amy S. Paller, A.S. Paller, Marieke M.B. Seyger +27 · 25 citations
   Immunology and Microbiology · Medicine · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Dermatology and Skin Diseases